Acrivon Therapeutics

Acrivon Therapeutics Employees

19 people indexed:

Adam D. Levy

Investor Relations and Corporate Affairs

4j.zht2@bhbx77h.ptk Sign up to see email

tg.8h59@g36spkw.7f3 Sign up to see email
Bruce Close

Quality and Compliance

p4py4k@86zzhu1.t95 Sign up to see email

g0yu37@492w1y5.j0h Sign up to see email
David Proia

Biology and Drug Discovery

4f1ugu@8yh5y5f.bhu Sign up to see email

20xg70@xx3ffjl.jek Sign up to see email
Eric Devroe

Chief Operating Officer

usw4bbj@zx062gu.fqj Sign up to see email

tqqs04p@q2k4jfk.86s Sign up to see email
Erick Gamelin

Chief Development Officer

x4pqt4u8@3d12zud.bpt Sign up to see email

db7qs82k@hkfuj5y.f82 Sign up to see email
James Dunyak

Biostatistics

674l15b@q72gwzq.gzt Sign up to see email

9ts65gx@s4p24l0.6ws Sign up to see email
Jean-Marie Cuillerot

Chief Medical Officer

k82g3gw75k@8w9bqwp.47g Sign up to see email

z901wh7pqd@h1kdgdz.wyy Sign up to see email
John van Duzer

Chemistry Manufacturing and Controls

k1g4.60bg4@s7sf0fh.byt Sign up to see email

lx7l.tbfw4@4bsqbbx.12k Sign up to see email
Joon Jung

Data Science

qdlbx@0plqtt8.7xp Sign up to see email

e6eq5@387295f.9zl Sign up to see email
Katharine Peterson

Finance & Accounting

qwl163hwl@yjq6bzy.455 Sign up to see email

w608162fj@31jj80g.57d Sign up to see email
Kristina Masson

Co-Founder, EVP, Business Operations, Site Head, Director

82q5qg7@0qbg7q1.690 Sign up to see email

58t6lqu@t358lh0.99f Sign up to see email
Mary-Alice Miller

Chief Legal Officer

3568tg9@k72q5ht.3h0 Sign up to see email

xgshx47@fzf8sh4.9ht Sign up to see email
Michail Shipitsin

Biomarker Development

966bwbb3y5@e6g1x87.1kb Sign up to see email

e209dgl2y1@kfy94b7.w5f Sign up to see email
Monica Phadnis

Clinical Operations

ujg607q7@819u4jx.4gk Sign up to see email

f38u6q39@k79lg30.t0y Sign up to see email
Parvin Miah

Human Resources

exeyz@kqbg91x.x0k Sign up to see email

27gu1@4b6f4ke.08j Sign up to see email
Peter Blume-Jensen

CEO, President, FounderChairperson

yzk4w1f55yytk@g2tgzd2.g1q Sign up to see email

824d1g4f2d298@2w9g10k.d1d Sign up to see email
Praveen Marapaka

Global Regulatory Affairs

63h6j3ebq@q96w5d0.e86 Sign up to see email

jd7w37ye1@7e0fy0d.uw1 Sign up to see email
Rajshree Kandadai

Business Development

zu6z6put1@j38035p.11g Sign up to see email

54j64447q@2gj1yex.fyj Sign up to see email
Rasmus Holm-Jorgensen

Chief Financial Officer

q28wkzdb32bpk37@kf6zf17.847 Sign up to see email

kk983zq3u75q5w1@k95b7z8.8qd Sign up to see email

Acrivon Therapeutics Company Information

Acrivon Therapeutics is a biotechnology company focused on developing precision oncology medicines tailored to patients whose tumors are predicted to respond to specific treatments. The company employs its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), to match treatments to patients. Acrivon’s lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently undergoing a potentially registrational Phase 2 trial across multiple tumor types. The FDA has granted Fast Track designation for ACR-368 as a monotherapy for patients with platinum-resistant ovarian or endometrial cancer. Additionally, the FDA awarded Breakthrough Device designation for the ACR-368 OncoSignature assay, which identifies ovarian cancer patients likely to benefit from ACR-368 treatment. The company is also developing internally-discovered preclinical stage pipeline programs, including ACR-2316, a selective dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics is headquartered in Watertown, Massachusetts, with additional operations in Lund, Sweden.

Report inaccurate information